Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial.
Lancet Infect DisJun 11, 2026 (epub)
Caitlin Pley, David J Jeffries, Ebrima Kanteh et al.
✦ AI-curated · Sources linked
In 30 seconds
This open-label, non-randomised, single-site, phase 3 trial evaluated the safety and immunogenicity of a yellow fever booster in 610 healthy Gambian children aged 1-9 years. After vaccination, 581 (99%) children were seropositive, with the oldest and middle cohorts showing a greater fold change in neutralising antibodies compared to the youngest cohort.
Key findings
- 99% of children were seropositive post-booster vaccination.
- The oldest cohort had a fold change in neutralising antibody of 7.72.
- The middle cohort had a fold change of 6.13, while the youngest cohort had 4.62.
- Two severe adverse events occurred, neither related to the vaccine.
Why it matters
Understanding the safety and immunogenicity of yellow fever booster vaccinations in children is crucial for public health strategies, especially in endemic regions where vaccine-induced immunity may wane.